AmerisourceBergen Corp. (NYSE: ABC), Valley Forge, PA, reported sales for the third quarter ended June 30 of $21.9 billion, up 13.3 percent over the same period a year ago. Sales growth was driven by a 16 percent increase in AmerisourceBergen Drug Corp. revenue and a 5 percent increase in AmerisourceBergen Specialty Group revenue.

Profit fell 7 percent to $168.4 million.

For the first nine months of the fiscal year, sales were $63.5 billion, up 7.6 percent year over year. Profit fell 31 percent to $382.7 million.

"In our June quarter, AmerisourceBergen delivered solid performance and made significant progress on strategic initiatives,” said Steven H. Collis, president and CEO. “We completed two previously announced divestitures, obtained the required regulatory approvals on certain aspects of our new strategic long-term relationship with Walgreen Co. and Alliance Boots GmbH, and have begun to prepare our network for the onboarding of the new Walgreens distribution contract in September.

"In addition, we recently enhanced our financial flexibility by increasing the borrowing capacity of our revolver and our securitization programs. Not only are we on track to meet our objectives for the full fiscal year, but we have taken important steps to strengthen our ability to generate sustainable long term growth that benefits all of our stakeholders.”